CURATIS N AG - Asset Resilience Ratio
CURATIS N AG (CURN) has an Asset Resilience Ratio of 3.75% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is CURATIS N AG's working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2024)
This chart shows how CURATIS N AG's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is CURATIS N AG's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down CURATIS N AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read CURN current and long-term liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF2.04 Million | 3.75% |
| Short-term Investments | CHF0.00 | 0% |
| Total Liquid Assets | CHF2.04 Million | 3.75% |
Asset Resilience Insights
- Limited Liquidity: CURATIS N AG maintains only 3.75% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
CURATIS N AG Industry Peers by Asset Resilience Ratio
Compare CURATIS N AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 0.50% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Neuland Laboratories Limited
NSE:NEULANDLAB |
Drug Manufacturers - Specialty & Generic | 9.65% |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062 |
Drug Manufacturers - Specialty & Generic | 1.18% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
Annual Asset Resilience Ratio for CURATIS N AG (2022–2024)
The table below shows the annual Asset Resilience Ratio data for CURATIS N AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 5.43% | CHF3.01 Million ≈ $3.81 Million |
CHF55.54 Million ≈ $70.21 Million |
+5.42pp |
| 2022-12-31 | 0.01% | CHF1.00K ≈ $1.26K |
CHF14.05 Million ≈ $17.76 Million |
-- |
About CURATIS N AG
Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson's disease, cyanide poisoning, digoxin toxicity, antih… Read more